Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00186355

Enrollment

Registered

2005-09-16

Start date

2003-10-31

Completion date

2010-02-28

Last updated

2012-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Non-Hodgkin

Brief summary

To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.

Detailed description

To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).

Interventions

PROCEDUREhigh dose chemo then auto hematopoietic cell transplant

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

4 Weeks to 75 Years

Healthy volunteers

Inclusion criteria

- relapsed NHL

Exclusion criteria

- liver dysfunction

Design outcomes

Primary

Measure	Time frame
PCR positivity in peripheral blood cell collections after cyclophosphamide	—

Secondary

Measure	Time frame
Enrichment of hematopoietic stem cells	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026